Form 4: Werewolf Therapeutics Director Alon Lazarus Granted 27,000 Stock Options

Werewolf Therapeutics, Inc. Director Alon Lazarus was granted 27,000 stock options with an exercise price of $1.29 per share, vesting over one year or by the next annual meeting.

Summary

• Alon Lazarus, a Director of Werewolf Therapeutics, Inc. (HOWL), was granted 27,000 stock options.
• The options have an exercise price of $1.29 per share.
• The grant date for these options was June 12, 2025.
• The options vest in full on the earlier of the first anniversary of the grant date (June 12, 2026) or the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Lazarus's continued service as a director.
• The options expire on June 11, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with shareholder value creation, and this is a routine, expected disclosure for insider transactions.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• The exercise price of $1.29 per share provides a clear benchmark for future stock price appreciation that would benefit the director and, by extension, shareholders.

Risks

• The value of the granted stock options is directly dependent on the future market price of Werewolf Therapeutics, Inc. common stock, which is subject to market fluctuations and company performance.
• The vesting of the options is subject to the reporting person's continued service as a director; if service ceases before vesting, the unvested options may be forfeited.

Future Outlook

The grant of stock options to Director Alon Lazarus indicates an incentive for his continued service and aligns his financial interests with the future performance and stock price appreciation of Werewolf Therapeutics, Inc.

Industry Context

The grant of equity compensation, such as stock options, to directors is a common practice in the biotechnology and pharmaceutical industries to attract and retain talent, and to align the interests of leadership with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize long-term performance.
• The specific number of options (27,000) and exercise price ($1.29) would typically be evaluated against peer companies' director compensation packages, considering the company's stage of development, market capitalization, and the director's specific role and contributions. Without specific peer data, a direct quantitative comparison is not feasible from this document alone.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, potentially leading to more focused efforts on increasing stock price.
• Employees: No direct impact on general employees is mentioned in this specific filing.

Next Steps

• The options will vest in full on the earlier of June 12, 2026, or the next annual meeting of stockholders following the grant date, subject to continued service.
• The director may exercise these options at any time after vesting and before the expiration date of June 11, 2035.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Alon Lazarus, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotechnology